## Fiscal Note

State of Alaska Bill Version: **SB 32** 2017 Legislative Session Fiscal Note Number: () Publish Date: Identifier: SB032-DCCED-CBPL-02-03-17 Department: Department of Commerce, Community and Title: PRESCRIPTIONS FOR BIOLOGICAL PRODUCTS **Economic Development** Sponsor: **HUGHES** Appropriation: Corporations, Business and Professional Requester: (S) HSS Licensing Allocation: Corporations, Business and Professional Licensina OMB Component Number: 2360 Expenditures/Revenues Note: Amounts do not include inflation unless otherwise noted below. (Thousands of Dollars) Included in FY2018 Governor's Appropriation FY2018 **Out-Year Cost Estimates** Requested Request **OPERATING EXPENDITURES** FY 2018 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 Personal Services Trave! Services 4.5 Commodities Capital Outlay **Grants & Benefits** Miscellaneous **Total Operating** 4.5 0.0 0.0 0.0 0.0 0.0 0.0 Fund Source (Operating Only) 1156 Rcpt Svcs (DGF) 4.5 Total 4.5 0.0 0.0 0.0 0.0 0.0 0.0 **Positions** Full-time Part-time Temporary Change in Revenues 1156 Rcpt Svcs (DGF) 4.5 Total 0.0 0.0 0.0 0.0 0.0 0.0 Estimated SUPPLEMENTAL (FY2017) cost: (separate supplemental appropriation required) (discuss reasons and fund source(s) in analysis section) Estimated CAPITAL (FY2018) cost: (separate capital appropriation required) (discuss reasons and fund source(s) in analysis section) **ASSOCIATED REGULATIONS** Does the bill direct, or will the bill result in, regulation changes adopted by your agency? Yes If yes, by what date are the regulations to be adopted, amended or repealed? 07/01/18 Why this fiscal note differs from previous version: Not applicable, initial version.

Prepared By:	Janey Hovenden, Director	Phone:	(907)465-2538
Division:	Corporations, Business and Professional Licensing	Date:	02/03/2017 12:00 PM
Approved By:	Catherine Reardon, Director	Date:	02/03/17
Agency:	Division of Administrative Services, DCCED		<b></b>

Printed 2/6/2017

## FISCAL NOTE ANALYSIS

## STATE OF ALASKA 2017 LEGISLATIVE SESSION

BILL	NO.	SB 32	
------	-----	-------	--

## **Analysis**

SB 32 allows a substitution of a prescription for a biological product with an interchangeable biological product. If the original prescribed product is not available in the pharmacy or is more expensive than an interchangeable product, the pharmacist may choose to dispense the interchangeable product. Substitution would allow for more availability of a biological product, and lower cost to the patient. This bill requires the pharmacy to contact the prescribing practitioner if a substitution of the original prescription of a biological product is made with an interchangeable biological product. In addition this bill requires the Board of Pharmacy to post and maintain a link to the US Food and Drug Administration's list of all currently approved interchangeable biological products on the board's website. The bill does not specifically change the pharmacy licensing program. However, it does allow a broader scope for a pharmacist to dispense an equivalent product more available to a patient. If the bill passes the division will require \$4.5 for legal costs to amend regulations, printing, and postage in the first year. Professional licensing programs within the Division of Corporations, Business and Professional Licensing are funded by Receipt Supported Services, fund source 1156 Rcpt Svcs (DGF). Licensing fees for each occupation are set per AS 08.01.065 so the total amount of revenue collected approximately equals the occupation's actual regulatory costs.

(Revised 8/12/16 OMB/LFD)

Page 2 of 2